Source: Tech – South China Morning PostAre Chinese biotechnology players becoming the focal point of friction under the broken US-China ties?Recent events and data are stoking speculation that it will be the next flashpoint involving mainland Chinese drug producers and US government departments and regulatory authorities, some analysts suggested, as competition in the market for cures intensifies amid the pandemic.On February 7, the US added WuXi Biologics and 32 other Chinese firms to its “unverified list” in a move that entails…Read More